Bengaluru, July 17 -- One of India's leading pharmaceutical exporters has further expanded its U.S. portfolio with the launch of a new ophthalmic product. The development is expected to strengthen the company's position in the lucrative U.S. generics market, even as it continues to post strong financial growth supported by a solid global presence.

The company in focus is Lupin Limited, which currently holds a market capitalization of Rs. 89,288 crore. The stock opened today at Rs. 1,938, slightly higher than its previous close of Rs. 1,930.10, and climbed to an intraday high of Rs. 1,961.60, reflecting a modest gain of approximately 1.63 percent.

Published by HT Digital Content Services with permission from Trade Brains....